NCT04684940 - Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2029

Conditions

Hemophilia A With InhibitorHemophilia A With Anti Factor VIII

Interventions

BIOLOGICAL

Valoctocogene roxaparvovec

Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A

Trial Locations (9)

Children's Hospital Los Angeles, Los Angeles

Hemocentro Da UNICAMP, Campinas

Arthur De Siqueira Cavalcanti Hematology State Institute, Rio de Janeiro

Chaim Sheba Medical Center, Ramat Gan

Kyung Hee University Hospital at Gangdong, Seoul

Kaohsiung Medical University - Chung-Ho Memorial Hospital, Kaohsiung City

Taichung Veterans General Hospital, Taichung

National Taiwan University Hospital, Taipei

Ege University School of Medicine, Izmir